Skip to main content
SpringerLink
Log in

Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The accelerated blood clearance (ABC) phenomenon is induced by repeated intravenous injection of stealth polyethylene glycol (PEG) nanocarriers and appears as the alteration of the pharmacokinetics and biodistribution of the second administration. Nevertheless, there is no any report about the ABC phenomenon induced by intraperitoneal administration of PEGylated nanocarriers. In this study, we firstly observed whether the ABC phenomenon is induced with PEGylated nanoemulsion at the dose of 0.5~100 μmol phospholipid·kg−1 by intraperitoneal/intravenous injections in rats. The PEG (molecule weight, 2000)-modified nanoemulsions PE-B and PE in which fluorescence indicator dialkylcarbocyanines (DiR) is encapsulated by PE-B were prepared for this work. The pharmacokinetics of the first injected PE via veins or peritoneal cavity features different variation trends. Moreover, the tissue distributions (in vivo or in vitro) of the first injected PE by intraperitoneal injection reveals that the PE gains access to the whole lymphatic circulatory system. Furthermore, our results demonstrate that the ABC phenomenon can be induced by intraperitoneal administration PE-B and present obvious changes with varying PE-B concentration 0.5~100 μmol phospholipid·kg−1. Moreover, an interesting point is that the ABC phenomenon induced by intraperitoneal injected PE-B can be significantly inhibited by intraperitoneal pre-injection of distilled water. For understanding this issue clear, we studied the production of anti-PEG IgM and the characteristic morphologies of immune cells. We observed that the mast cells in peritoneal cavity exhibit rapid depletion in response to the intraperitoneal pre-injection of distilled water, while the anti-PEG IgM secretes at the same level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1–20.

    Article  CAS  PubMed  Google Scholar 

  2. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets. 2004;5(5):449–55.

    Article  CAS  PubMed  Google Scholar 

  4. Bunker A, Magarkar A, Viitala T. Rational design of liposomal drug delivery systems, a review: combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. Biochim Biophys Acta. 2016;1858(10):2334–52.

    Article  CAS  PubMed  Google Scholar 

  5. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6(4):715–28.

    Article  CAS  PubMed  Google Scholar 

  6. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van der Meer JW, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071–9.

    CAS  PubMed  Google Scholar 

  7. Laverman P, Carstens MG, Boerman OC, Dams ETM, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607–12.

    CAS  PubMed  Google Scholar 

  8. Ishida T, Maeda R, Ichihara M, Mukai Y, Motoki Y, Manabe Y, et al. The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study. Cell Mol Biol Lett. 2002;7(2):286.

    PubMed  Google Scholar 

  9. Lila ASA, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172(1):38–47.

    Article  CAS  PubMed  Google Scholar 

  10. Im H-J, England CG, Feng L, Graves SA, Hernandez R, Nickles RJ, et al. Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated nanoparticles in peripheral arterial disease. ACS Appl Mater Interfaces. 2016;8(28):17955–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res. 2009;26(10):2270–9.

    Article  CAS  PubMed  Google Scholar 

  12. Zhao Y, Wang L, Yan M, Ma Y, Zang G, She Z, et al. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine. 2012;7:2891.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm. 2008;362(1–2):197–200.

    Article  CAS  PubMed  Google Scholar 

  14. Shiraishi K, Yokoyama M. Polymeric micelles possessing polyethyleneglycol as outer shell and their unique behaviors in accelerated blood clearance phenomenon. Biol Pharm Bull. 2013;36(6):878–82.

    Article  CAS  PubMed  Google Scholar 

  15. Środa K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett. 2005;10:37–47.

    PubMed  Google Scholar 

  16. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release. 2006;115(3):243–50.

    Article  CAS  PubMed  Google Scholar 

  17. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  18. Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2013;218(5):725–32.

    Article  CAS  PubMed  Google Scholar 

  19. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349–55.

    Article  CAS  PubMed  Google Scholar 

  20. Ishida T, Kashima S, Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Control Release. 2008;126(2):162–5.

    Article  CAS  PubMed  Google Scholar 

  21. Shimizu T, Mima Y, Hashimoto Y, Ukawa M, Ando H, Kiwada H, et al. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells. Immunobiology. 2015;220(10):1151–60.

    Article  CAS  PubMed  Google Scholar 

  22. Wang L, Su Y, Wang X, Liang K, Liu M, Tang W, et al. Effects of complement inhibition on the ABC phenomenon in rats. Asia J Pharmaceut Sci. 2017;12(3):250–8.

    Google Scholar 

  23. Zhao Y, Wang C, Wang L, Yang Q, Tang W, She Z, et al. A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. Eur J Pharm Biopharm. 2012;81(3):506–13.

    Article  CAS  PubMed  Google Scholar 

  24. Ishida T, Ichikawa T, Ichihara M, Sadzuka Y, Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release. 2004;95(3):403–12.

    Article  CAS  PubMed  Google Scholar 

  25. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105(3):305–17.

    Article  CAS  PubMed  Google Scholar 

  26. Peng K-W, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62(16):4656–62.

    CAS  PubMed  Google Scholar 

  27. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315–25.

    Article  PubMed  Google Scholar 

  28. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692–8.

    Article  PubMed  Google Scholar 

  29. Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin D, Schulz TK, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer Chemother Pharmacol. 2015;75(5):1075–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol. 2005;1(6):755–62.

    Article  CAS  PubMed  Google Scholar 

  31. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, JL-S A. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327(3):673–82.

    Article  CAS  PubMed  Google Scholar 

  32. Xu S, Fan H, Yin L, Zhang J, Dong A, Deng L, et al. Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis. Eur J Pharm Biopharm. 2016;104:251–9.

    Article  CAS  PubMed  Google Scholar 

  33. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.

    Article  CAS  PubMed  Google Scholar 

  34. Liang K, Wang L, Su Y, Liu M, Feng R, Song Y, et al. Comparison among different “revealers” in the study of accelerated blood clearance phenomenon. Eur J Pharm Sci. 2018;114:210–6.

    Article  CAS  PubMed  Google Scholar 

  35. Yen-Rei AY, O’Koren EG, Hotten DF, Kan MJ, Kopin D, Nelson ER, et al. A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues. PLoS One. 2016; https://doi.org/10.1371/journal.pone.0150606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Horny H-P, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am. 2014;34(2):315–21.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–744.

    CAS  PubMed  Google Scholar 

  38. Dobrovolskaia MA, McNeil SE. Handbook of immunological properties of engineered nanomaterials. 3rd ed. World Scientific: CRC Press; 2013.

    Book  Google Scholar 

  39. Wang J, Kubes P. A reservoir of mature cavity macrophages that can rapidly invade visceral organs to affect tissue repair. Cell. 2016;165(3):668–78.

    Article  CAS  PubMed  Google Scholar 

  40. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer. 2000;88(2):358–63.

    Article  CAS  PubMed  Google Scholar 

  42. Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–85.

    Article  PubMed  Google Scholar 

  43. Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15(1):339–44.

    Article  PubMed  Google Scholar 

  44. Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14(1):148–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori. 2001;87(3):120–6.

    Article  CAS  PubMed  Google Scholar 

  46. Beutler B, Milsark I, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229(4716):869–71.

    Article  CAS  PubMed  Google Scholar 

  47. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004;10(2):187–92.

    Article  CAS  PubMed  Google Scholar 

  48. MacQueen G, Marshall J, Perdue M, Siegel S, Bienenstock J. Pavlovian conditioning of rat mucosal mast cells to secrete rat mast cell protease II. Science. 1989;243(4887):83–5.

    Article  CAS  PubMed  Google Scholar 

  49. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6(2):135–42.

    Article  CAS  PubMed  Google Scholar 

  50. Jatana S, Palmer BC, Phelan SJ, DeLouise LA. Immunomodulatory effects of nanoparticles on skin allergy. Sci Rep. 2017;7(1):3979–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was aided financially by the National Natural Science Foundation of China (Grant Nos. 81072602, 81373334).

Author information

Authors and Affiliations

  1. School of Pharmacy, Shenyang Pharmaceutical University, 26 Huatuo Road, Benxi, 117004, People’s Republic of China

    Yuqing Su, Mengyang Liu, Kaifan Liang, Xinrong Liu, Yanzhi Song & Yihui Deng

Authors
  1. Yuqing Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mengyang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaifan Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinrong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanzhi Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yihui Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yanzhi Song or Yihui Deng.

Electronic Supplementary Material

ESM 1

(DOCX 796 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, Y., Liu, M., Liang, K. et al. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration. AAPS PharmSciTech 19, 3210–3218 (2018). https://doi.org/10.1208/s12249-018-1120-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-018-1120-2

KEY WORDS

Search

Navigation